Biological systems underlying disease are complex, and targeting a single receptor or pathway through monotherapy rarely delivers maximal benefit. Cancer immunotherapy studies have shown that combining two antibodies can yield improved outcomes compared to single-agent therapy.

At Sound Biologics, we’re developing technologies that address this unmet need by enabling multi-pathway intervention within one therapeutic product—streamlining treatment and enhancing clinical potential. Our approach leverages the innovations to create versatile, next-generation therapeutics for greater efficacy and accessibility.

MabPair Platform. Our proprietary MabPair Platform enables the design of antibody combinations that act synergistically, reducing the potential for tumor escape or drug resistance. This approach also improves administration convenience and lowers cost compared with traditional antibody cocktails, while maintaining full flexibility in molecular design.

Bispecific Platform. Our complementary Bispecific Platform expands our ability to create stable heterodimeric antibodies expressed and purified through standard production methods—empowering the discovery of novel therapeutic candidates for diverse and complex disease targets.

The leadership team has extensive experience in antibody engineering, immuno-oncology, and related therapeutic areas, as well as in CMC development and regulatory submissions. They have successfully brought biologic drugs from discovery to patients through coordinated efforts in R&D.

Our first MabPair immuno-oncology therapy has reached patients in China, and we are actively advancing additional programs in inflammation, immune modulation, and neurology. Our leadership team’s expertise and commitment continue to guide Sound Biologics toward steady, science-driven growth.